[
    [
        {
            "time": "",
            "original_text": "药明康德涨近3%暂两连扬，破顶兼再次晋身红底股",
            "features": {
                "keywords": [
                    "药明康德",
                    "涨近3%",
                    "两连扬",
                    "破顶",
                    "红底股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德涨近3%暂两连扬，破顶兼再次晋身红底股",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【药明康德】大幅拉升0.61%，股价创近2个月新高",
            "features": {
                "keywords": [
                    "药明康德",
                    "大幅拉升",
                    "0.61%",
                    "2个月新高"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【药明康德】大幅拉升0.61%，股价创近2个月新高",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "英派药业CEO包骏博士：“合成致死”抗癌，大有可为！",
            "features": {
                "keywords": [
                    "英派药业",
                    "CEO",
                    "包骏",
                    "合成致死",
                    "抗癌"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "英派药业CEO包骏博士：“合成致死”抗癌，大有可为！",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]